Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment.
It is increasingly clear that both adult and pediatric glial tumor entities represent collections of neoplastic lesions, each with individual pathological molecular events and treatment responses. In this review, we discuss the current prognostic biomarkers validated for clinical use or with future clinical validity for gliomas. Accurate prognostication is crucial for managing patients as treatments may be associated with high morbidity and the benefits of high risk interventions must be judged by the treating clinicians. We also review biomarkers with predictive validity, which may become clinically relevant with the development of targeted therapies for adult and pediatric gliomas.
Department of Neuropathology, Frenchay Hospital , Bristol , UK.
Harry R
HR
Haynes
Department of Neuropathology, University of Michigan , Ann Arbor, MI , USA.
Sandra
S
Camelo-Piragua
Department of Neuropathology, Frenchay Hospital , Bristol , UK.
Kathreena M
KM
Kurian
gliomas; predictive biomarkers; prognostic biomarkers